Abstract 83P
Background
VG2025 is a non-attenuated HSV-1 Oncolytic virus (OV) with the payloads IL-12, IL-15, and IL-15Ra and a Carcinoembryonic Antigen (CEA) specific promoter for ICP27. Here, we reported a first-in-human, open-label study to evaluate the safety and efficacy of VG2025 in patients (pts) with advanced solid tumors that progressed after standard care, conducted in China.
Methods
3+3 Dose escalation design with 5 dose levels as intratumoral injections on days 1 and 15 of each 28-day cycle. Preliminary safety, efficacy (per RECIST v1.1), PK, viral shedding and the immune biomarkers were analyzed.
Results
The preliminary findings of this study were presented at ASCO 2023, here we present updated results of additional dose levels. As of Aug 8, 2023, 14 pts received doses of 1.0x10ˆ8 PFU (n=3), 2.0x10ˆ8 PFU (n=3), 4.0x10ˆ8 PFU (n=3), and 6.0x10ˆ8 PFU (n=5) of each cycle. The longest duration of treatment was more than 11 cycles and the treatment is still ongoing. There were 11 males and 3 females with a median age of 51.5 (41-74). 57.1% were PD(L)1 refractory, 28.6% had 2 prior lines of therapy, and 64.3% had 3 or more prior lines of therapy. The mean CEA level was 29.1 (normal range of 0-5 μg/L). Tumor types included 4 CRC, 2 Duodenal adenocarcinoma, 2 HCC, 2 Pancreatic cancer, 1 NSCLC, 1 ICC, 1 NEC and 1 Neuroendocrine cancer. No DLTs were observed. The incidence of TRAEs and Gr≥3 TRAEs were 92.9% and 50.0%, with fever being the most common TRAE. 4 pts had 7 SAEs, which were unrelated to VG2025. No TRAEs led to dose reduction or treatment discontinuation. No pts had positive viral shedding. Of 9 evaluable pts, the ORR was 22.2% (with 2 PRs: 1 ICC pt and 1 NEC pt) and the DCR was 77.8%. The PR pts showed meaningful reductions in CEA levels. Tumor shrinkage was also observed in non-injected lesions, demonstrating an abscopal effect. Nanostring analysis of paired biopsies from the PR pts demonstrated upregulation of integrin signaling pathway, antigen-presenting MHC (HLA-DQA1 and HLA-DRB1) and chemokine receptor (CMKLR1) genes, and activation of CD8+ T cells.
Conclusions
Monotherapy with VG2025 demonstrated activity with a well-tolerant safety profile in pts with advanced solid tumors that progressed after standard of care therapy.
Clinical trial identification
NCT05477849.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Virogin Biotech Co., Ltd.
Funding
Has not received any funding.
Disclosure
Y. Shen, T. Liang: Financial Interests, Personal, Coordinating PI: Virogin. S. Rahimian, A. Qin, Y. Qiu, Q. Tan, R. Zhao: Financial Interests, Personal, Full or part-time Employment: Virogin. All other authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract